Artgen Seed Fund, the seed venture fund of Artgen Biotech (MOEX: ABIO), has summarized the results of its work with the investment pipeline in 2025 and outlined its strategic priorities for 2026.
During the reporting period, the Fund's activities focused on expert selection, structuring, and risk mitigation for early-stage knowledge-intensive projects in the biotechnology, digital health, and MedTech segments.
Artgen Seed Fund views capital as part of a broader ecosystemic support system, as access to infrastructure, industry expertise, and the market is critically important for Life Sciences projects. In 2025, project support included regulatory and clinical consulting, assistance in shaping B2B and B2G market entry strategies, and investment enhancement of projects to an institutional level.
"The quality of the entire future Life Sciences market is shaped at the seed stage. Our goal is not the number of transactions, but the early identification and structuring of viable scientific ‑and technological hypotheses that can be scaled both within the Artgen Biotech ecosystem and beyond it," noted Arthur Isaev, Chairman of the Board of Directors of Artgen Biotech.
During 2025, the Fund's team conducted in-depth analysis of more than 80 projects at the pre-seed and seed stages.
The projects were distributed by direction as follows:
This ratio ensures a balance between fundamental R&D with long-term IP‑potential and digital solutions with a faster path to market. A key element of the Fund's strategy is a reproducible project selection methodology. Project selection is based on three main factors: scientific validity and evidence base, regulatory feasibility and clinical pathway, and commercial logic and market potential.
Based on the selection results in 2025, Artgen Seed Fund identified three investment projects for financing. The Fund uses various financing and structuring instruments depending on the maturity stage of the project and the level of hypothesis validation.
In 2026, the Fund plans to scale its work with the investment pipeline, paying special attention to the formation of sustainable technological niches. Key areas of the Fund's work for 2026 include: neuroscience and complex MedTech, digital solutions for clinical trials, including electronic data capture (EDC) systems, and the development of syndications and the Fund's role as a lead‑investor for partners.